Genetic Technologies says Agilent denied motion to dismiss patent suit Genetic Technologies (GENE) announced that the United States District Court for the Northern District of California has last week issued an Order denying a motion brought by Agilent Technologies (A) to dismiss the patent infringement law suit brought against it by GTG. This action was initially brought by GTG against Agilent in 2011, in the District Court of Colorado, but was then moved at the request of Agilent to the District Court in the Northern District of California. GTG Acting CEO Tom Howitt repeated: “With the removal of what some potential licensees have apparently used as a reason to delay settlement discussions, we trust that good faith negotiations will now resume in earnest.”
Agilent will will no longer include orders in financial reporting Agilent Technologies announced it will no longer report orders in its periodic filings with the SEC or its quarterly earnings press releases, effective immediately. This change reflects feedback from several of the company's largest shareholders, and was also driven by the fact that Agilent was the only company among its peers to report orders. The other financial metrics included in the company's reporting provide comprehensive detail about Agilent's performance.